iCliniq Logo
HomeAnswersMedical oncologycancer immunotherapy

Does shorter immunotherapy duration benefit in NSCLC?

This Premium Q&A, reviewed and published, features a real conversation between an iCliniq user and a physician.

Patient's Query

Hi doctor,

My father was diagnosed with metastatic NSCLC lung cancer, which spread to the ninth and eighth ribs of the chest (all other organs are still not affected). Two cycles of chemotherapy were completed in the last one and a half months with 21-day intervals. Now the doctor suggested chemotherapy plus immunotherapy.

And as per the doctor, if immunotherapy works, then it will be continued for at least two years. But immunotherapy is very expensive. We do not think we can continue for up to two years, so my question is, if we continue the immunotherapy for a few months, like eight to ten months, will it give some kind of benefit compared to no immunotherapy at all?

Please help.

Hi,

Welcome to icliniq.com.

I have gone through your query and can understand your concerns.

Usually, immunotherapy plus chemotherapy is suggested for two years as per international guidelines.

Its duration can be reduced if the PET scan shows a complete response (complete resolution of disease). Then it can be stopped earlier. Also, there is upcoming evidence that immunotherapy at a reduced dose provides similar benefits as a full dose, which can help in reducing costs.

I would like to see the reports of

1. PET (positron emission tomography), CT (computed tomography).

2. NGS (next-generation sequencing) report for molecular testing.

3. PD-L1 (immunotherapy) testing.

These reports can give me an idea about the exact nature and type of lung cancer your father has.

I hope this helps.

Patient's Query

Hi doctor,

Here is the molecular testing report. As discussed with the doctor before, the PD-L1 score is less than 1%. He told me that as there is no targetable mutation, immunotherapy is a good option in this case. So, the doctor suggested chemotherapy (Pemetrexed and Carboplatin) with immunotherapy. I have the HRCT (high-resolution computed tomography) thorax report with me. I do not think any PET scan has been performed. I will double-check. For the moment, I have these reports.

Thank you.

Hi,

Welcome back to icliniq.com.

I read your query and can understand your concern.

1. NGS does not show any targetable mutations. In that case, immunotherapy plus chemotherapy becomes the best option.

2. Immunotherapy is generally effective if PD-L1 is positive. Need to see that report before confirming.

Reduced-dose immunotherapy has shown similar efficacy in a subset of lung cancer as well as other cancers. You can discuss this option with your oncologist. Also, I would suggest getting systemic imaging done. Ideally, PET CT or CECT (contrast-enhanced computed tomography) of the chest, abdomen, and head is used to see if the disease has spread beyond the thorax.

I hope this helps.

Kindly revert in case of further queries.

Medically reviewed byiCliniq medical review team

Published At January 6, 2023
Reviewed AtDecember 12, 2025

Same symptoms don't mean you have the same problem. Consult a doctor now!

Listen to related tracks in our music library

Ask your health query to a doctor online

*guaranteed answer within 4 hours

Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.